Chondrial Therapeutics, a US-based mitochondrial disease therapy developer advancing research from Indiana University (IU) and Wake Forest University’s Baptist Medical Center, today obtained up to $22.6m in a series A round featuring Wake Forest’s Catalyst Fund.

The round was led by healthcare-focused investment firm Deerfield Management. Catalyst Fund is a $15m tech development vehicle launched by Wake Forest Innovations, the university’s tech transfer arm, and managed by Pappas Capital.

Founded in 2013, Chondrial Therapeutics has licensed a therapeutic candidate called…